Insulin pumps have lagged behind continuous glucose monitors in terms of market penetration due to their cost and the complex regulatory framework that surrounds them. Elizabeth Gasser, chief strategy officer at Tandem Diabetes spoke to Medtech Insight about these challenges and how the company is taking a slightly different approach to pumps.

The companies will link Abbott’s blood glucose monitoring devices to WeightWatchers’ smartphone apps and weight loss program.

Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.

Abbott’s FreeStyle Libre 3 system will soon be available in the US. It is 70% smaller than the Libre 2 while also providing better accuracy.